Journal of psychopharmacology (Oxford, England)
May 1, 2024
Thomas Knuijver, Rob Ter Heine, Arnt Schellekens et al.
15 citations
Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. The study was performed in 14...
Translational Psychiatry
January 19, 2024
Judit Biosca-Brull, Genís Ona, Lineth Alarcón-franco et al.
5 citations
Ibogaine (IBO) is an atypical psychedelic with a complex mechanism of action. To date, the mechanisms that may underlie its anti-addictive effects are still not defined. This study aims to identify changes in gene expression induced by a single oral dose of IBO in the cortex of mice by means of a transcriptomic analysis for the first time. Our results showed significant alterations in gene...
Journal of Psychoactive Drugs
2024
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira et al.
7 citations
Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid-1960s. To evaluate the interest in ibogaine's use as a therapeutic agent, we performed a scientometric analysis covering the last three decades (1993-2002, 2003-2012, and 2013-2022). A complementary analysis was performed to select and describe...
Frontiers in Neuroscience
2024
Demi Govender, Leila Moloko, Maria Papathanasopoulos et al.
10 citations
Ibogaine is a psychedelic alkaloid being investigated as a possible treatment for opioid use disorder. Ibogaine has a multi-receptor profile with affinities for mu and kappa opioid as well as NMDA receptors amongst others. Due to the sparsity of research into ibogaine's effects on white matter integrity and given the growing evidence that opioid use disorder is characterized by white matter...
Journal of Addictive Diseases
2024
Alexandra Arenson, Cynthia I Campbell, Ilan Remler
8 citations
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternative treatments. This narrative review aims to educate clinicians on the mechanisms of action, toxicity, and applications of psychoactive plant-based substances patients may be using to self-treat OUD and OW. We specifically discuss ayahuasca, ibogaine,...
Journal of psychopharmacology (Oxford, England)
December 1, 2023
Genís Ona, Ingrid Reverte, Giordano N. Rossi et al.
20 citations
There is a growing interest in studying ibogaine (IBO) as a potential treatment for substance use disorders (SUDs). However, its clinical use has been hindered for mainly two reasons: First, the lack of randomized, controlled studies informing about its safety and efficacy. And second, IBO's mechanisms of action remain obscure. It has been challenging to elucidate a predominant mechanism of...
October 1, 2023
Sarah Falkenhaug
1 citation
Substance use disorders are a debilitating psychiatric condition which contribute to significant personal, legal and economic problems worldwide. Current treatment options, such as pharmaceutical interventions or behavioural therapy, are not always utilised or effective at reducing symptoms. Ibogaine, a psychedelic compound deriving from root bark of the Tabernanthe iboga plant, has shown...
Pharmacological Research
April 1, 2023
Deborah C. Mash
37 citations
Ibogaine is a powerful psychoactive substance that not only alters perception, mood and affect, but also stops addictive behaviors. Ibogaine has a very long history of ethnobotanical use in low doses to combat fatigue, hunger and thirst and, in high doses as a sacrament in African ritual contexts. In the 1960's, American and European self-help groups provided public testimonials that a single...
Psychedelics as Psychiatric Medications
March 1, 2023
Deborah C. Mash
1 citation
Abstract Ibogaine has been used as a botanical preparation from the root bark of Tabernanthe iboga for over one hundred years, both as a crude preparation and as semisynthetic ibogaine. Extracts derived from this plant have a long history of traditional medicinal and ceremonial use in Western Africa. Ibogaine is a polypharmacology drug that acts on several neurotransmitter systems, including...
Drug and Alcohol Review
February 1, 2023
Borja J Rodríguez-cano, Maja Kohek, Genís Ona et al.
17 citations
Ibogaine is one of the alkaloids naturally found in plants such as Tabernanthe iboga, which has been traditionally used by members of the Bwiti culture. Since the discovery of its anti-addictive properties by Howard S. Lotsof in 1962, ibogaine has been used experimentally to treat substance use disorders (SUD), especially those involving opioids. We aim to provide a detailed understanding of...